Quizartinib Plus Chemotherapy Improves Survival vs Placebo in FLT3-ITD-Positive AML
Researchers sought to determine whether adding quizartinib to standard chemotherapy would improve survival in patients with newly diagnosed FLT3-ITD-positive AML.
Diagnosis & Disease Information
Substantial Proportion of Patients With MDS or AML Not Considered for HCT
Researchers sought to determine the proportion of potentially eligible patients with high-risk MDS or AML who are considered for HCT.
Mitophagy Appears to Drive BH3 Mimetic Resistance in AML
Researchers sought to determine whether reducing mitophagy would impact BH3 mimetic resistance in AML.
Nutrition-Related Challenges Common for Older Adults with AML, MDS
A literature review sought to identify nutritional challenges patients with acute myeloid leukemia and myelodysplastic syndrome experience.
Flow Cytometry-Based MRD May Be Prognostic in Children With KMT2A-Rearranged AML
Researchers sought to determine whether flow cytometry-based MRD at end of induction 2 would be a prognostic factor in pediatric KMT2A-rearranged AML.
FDA Extends Review Period for Quizartinib for FLT3-ITD Positive AML
Quizartinib is an oral, highly potent type II FLT3 inhibitor that selectively targets FLT3-ITD mutations.
IDH2 R172 Linked With Improved Survival in Myeloid Neoplasms
Researchers sought to determine whether IDH2 R172 mutations had an impact on survival in patients with myeloid neoplasms.
Venetoclax With Idasanutlin Show Promise in Acute Myeloid Leukemia
Researchers sought to determine whether venetoclax combined with idasanutlin would be safe and effective in patients with AML.
Increased Infection, Reduced Hematopoietic Stem Cell Transplantation Rates Seen in TP53-Mutated MDS/AML
Researchers sought to determine the impact of TP53 mutations on infection and HCT rates in patients with MDS/AML.
Genetic Variants Impact Residual Disease and Outcomes in Acute Myeloid Leukemia Allo-HSCT
Researchers sought to determine whether certain genetic variants would impact outcomes for patients with AML in first remission prior to undergoing allo-HSCT.
- Loading...
Loading...
Next post in Leukemia
Loading... 
Loading...